CIN (Cervical Intraepithelial Neoplasia) - Comprehensive 10-Mark Answer

Based on Berek & Novak's Gynecology

DEFINITION

• Cellular immaturity
• Cellular disorganization
• Nuclear abnormality (enlargement, hyperchromasia, irregular nuclear membranes)
• Increased mitotic activity

"The extent of the mitotic activity, immature cellular proliferation, and nuclear atypia identifies the degree of neoplasia." - Berek & Novak

CLASSIFICATION / GRADING

┌─────────────────────────────────────────────────────────────────┐
│              EPITHELIAL THICKNESS (Basal → Surface)             │
│                                                                 │
│  CIN 1  │▓▓░░░░░░░░░░│  Mitoses + immature cells = LOWER 1/3   │
│  (LSIL) │            │  60-85% SPONTANEOUS REGRESSION          │
│─────────────────────────────────────────────────────────────────│
│  CIN 2  │▓▓▓▓▓▓░░░░░│  Mitoses + immature cells = LOWER 2/3   │
│  (HSIL) │            │  20% progress to CIS; 5% to invasion    │
│─────────────────────────────────────────────────────────────────│
│  CIN 3  │▓▓▓▓▓▓▓▓▓▓▓│  Full thickness involvement              │
│  (HSIL) │            │  Includes Carcinoma In Situ (CIS)       │
│         │            │  5% CIS → invasion if untreated         │
└─────────────────────────────────────────────────────────────────┘

▓ = immature atypical cells with mitoses
░ = maturing cells

SITE OF ORIGIN

         CERVIX (CROSS-SECTION VIEW)
         ─────────────────────────────
         Endocervical canal
              │
         [Original SCJ] ←── Nabothian cysts / cleft openings
              │
         TRANSFORMATION ZONE ← CIN ORIGINATES HERE
         (metaplastic epithelium)
              │
         [Active/Physiologic SCJ]
              │
         Exocervix (original squamous epithelium)

• Anterior lip is twice as likely to develop CIN as the posterior lip
• CIN rarely originates in lateral angles
• CIN does not replace original squamous epithelium - has sharp external border

ETIOLOGY - HPV

• Persistent high-risk oncogenic HPV infection is the principal risk factor
• HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 account for ~90% of high-grade lesions
• HPV-16 is the most common in CIN 2, CIN 3, and invasive cancer
• Malignant transformation requires expression of E6 and E7 oncoproteins
• In the majority of cases, HPV clears spontaneously in 9-15 months

CYTOLOGIC CORRELATES (Bethesda System)

CYTOLOGY                    HISTOLOGY (CIN)
─────────────────────────────────────────────
ASC-US ──────────────→  CIN 1 (10-20%), CIN 2/3 (3-5%)
ASC-H  ──────────────→  CIN 2/3 (higher risk; refer to colposcopy)
LSIL   ──────────────→  CIN 1 (predominantly)
HSIL   ──────────────→  CIN 2/3 (high risk; immediate colposcopy)
AGC / AIS ───────────→  Adenocarcinoma in situ (specialized management)

COLPOSCOPIC FINDINGS

MANAGEMENT FLOWCHARTS

FLOWCHART 1: CIN 1 Management

            BIOPSY-PROVEN CIN 1
                    │
                    ▼
         What was the prior cytology?
        ┌──────────┴────────────────┐
        │                          │
   ASC-US / LSIL              ASC-H / HSIL
        │                          │
        ▼                          ▼
  Satisfactory               Higher risk scenario
  colposcopy                 (despite CIN 1 on biopsy)
        │                          │
        ▼                          ▼
 CO-TESTING at 12 months    Co-testing at 12 & 24 months
 (HPV + cytology)               OR
        │                     Loop Excision (LEEP)
        │
   ┌────┴────────┐
NEGATIVE       POSITIVE
(both HPV &    (any abnormality)
cytology)           │
   │               ▼
   ▼          Return to COLPOSCOPY
Return to
age-appropriate
screening

        IF CIN 1 PERSISTS ≥ 24 MONTHS:
        ┌──────────────────────────────────┐
        │ Adequate colposcopy?             │
        │   YES → Choice of:              │
        │     a) Continued surveillance   │
        │     b) Ablation/Excision of TZ  │
        │   NO  → Excision only           │
        │         (NOT ablation)          │
        └──────────────────────────────────┘

• CIN 1 is NOT a cancer precursor - it is a manifestation of HPV infection
• Spontaneous regression: 60-85% within 2 years
• Young women (21-24 years): cytology alone at 12 and 24 months (no HPV testing needed)

FLOWCHART 2: CIN 2 and CIN 3 Management

         BIOPSY-PROVEN CIN 2 / CIN 3
                    │
                    ▼
         Age and clinical context?
    ┌────────────────┴────────────────────┐
    │                                     │
 Age ≥ 25 years                    Age < 25 years
 (Standard management)             OR Pregnant
    │                                     │
    ▼                                     ▼
Adequate colposcopy?           Intensive observation:
    │                          - Colposcopy + cytology
 ┌──┴──┐                         at 6 and 12 months
 YES   NO                      - If normal at 12 months:
 │     │                         co-testing at 1 more year
 ▼     ▼                       (Acceptable for CIN 2
LEEP   CONIZATION               in young women, NOT CIN 3)
(preferred)                    ──────────────────────────
                               PREGNANT women:
    ▼                          - Cytology + colposcopy
Post-treatment                   until 6 weeks postpartum
CO-TESTING at                  - No treatment during pregnancy
12 and 24 months                 unless invasive cancer suspected
    │
 ┌──┴──┐
NEG   ABNORMAL
 │       │
 ▼       ▼
Return Colposcopy +
to     Biopsy ±
routine Retreatment
screening

• CIN 2 progresses to CIS in 20%, to invasion in 5% (meta-analysis)
• CIS progresses to invasion in 5% if untreated
• LEEP is the preferred treatment - allows pathological evaluation to rule out microinvasion
• Persistent/recurrent disease rate post-LEEP: 4-10%

TREATMENT MODALITIES IN DETAIL

1. CRYOTHERAPY

• Uses liquid nitrogen or nitrous oxide (probe temperature: -20 to -30°C)
• Freeze-thaw-freeze technique: 3 minutes freeze, 5 minutes thaw, 3 minutes freeze
• Best for: exocervical, small lesions with fully visible SCJ
• Contraindications: endocervical extension, large lesion (>75% ectocervix), inadequate colposcopy
• Success rate: ~85-90% for CIN 1-2

CRYOTHERAPY CRITERIA ("3 to 2 rule"):
✓ Lesion fits cryoprobe (≤ 3 zones of 5mm, ≤ 2 quadrants)
✓ Entire lesion visible
✓ No endocervical involvement
✓ No adenocarcinoma in situ
✗ NOT if lesion extends into canal

2. LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP)

• Uses a thin wire loop carrying electrical current to excise the TZ
• Preferred treatment for CIN 2-3: provides specimen for histopathology
• SCJ visible in >90% of patients after LEEP
• Complications: intraoperative hemorrhage, postoperative hemorrhage, cervical stenosis (low rates)
• Obstetric risk: increased risk of preterm delivery, PROM, low birth weight in future pregnancies

LEEP ADVANTAGES:
✓ Outpatient procedure under local anesthesia
✓ Provides specimen for histology
✓ Can detect occult microinvasive cancer
✓ Can detect adenomatous involvement
✓ SCJ visible after procedure (>90%)
✗ NOT before histologic diagnosis of HSIL confirmed
✗ NOT in pregnancy (unless invasive cancer suspected)

3. CONIZATION (Cold Knife / Laser)

• Diagnostic AND therapeutic procedure
• Provides specimen with accurate surgical margins assessment
• Indicated when:
  1. Limits of lesion cannot be visualized at colposcopy
  2. SCJ not evaluable at colposcopy
  3. ECC positive for CIN 2 or CIN 3
  4. Substantial discordance between cytology, biopsy, and colposcopy
  5. Microinvasion suspected
  6. Colposcopist unable to rule out invasive cancer
  7. CIN 3 or AGC-AIS requiring diagnostic conization

RECURRENCE RISK AFTER CONIZATION:
- Positive margins → higher recurrence
- Endocervical gland involvement:
    With gland involvement: 23.6% recurrence
    Without gland involvement: 11.3% recurrence

4. LASER ABLATION

• CO2 laser destroys transformation zone by vaporization
• Precision allows tissue destruction to exact depth needed
• Comparable cure rates to LEEP

5. HYSTERECTOMY

• Treatment of LAST RESORT - only for recurrent high-grade CIN
• Incidence of invasive cancer occurring after hysterectomy for CIN: 0.4% (in 8,998 women)
• Complications (bleeding, infection, death) are higher than with other modalities
• Valid indications for hysterectomy in CIN:
  • Recurrent high-grade CIN after excision + patient does not desire fertility
  • CIN with other gynecologic pathology requiring hysterectomy
  • Patient with inability to comply with surveillance

FLOWCHART 3: Cervical Adenocarcinoma In Situ (AIS) Management

     ADENOCARCINOMA IN SITU (AIS)
              │
              ▼
     Histologic diagnosis confirmed
              │
              ▼
     EXCISION (Cold-knife cone / LEEP)
     - Margins critical to assess
     - Skip lesions can occur
              │
        ┌─────┴──────┐
    NEGATIVE       POSITIVE
    margins        margins
        │               │
        ▼               ▼
  Desire future     Re-excision
  fertility?        (repeat cone)
   ┌────┴──────┐         │
   YES         NO        ▼
   │           │    If still positive /
   ▼           ▼    patient desires no
Surveillance HYSTERECTOMY  fertility:
(co-testing) (DEFINITIVE   HYSTERECTOMY
             TREATMENT)

• Endocervical glandular cells replaced by tall columnar cells with nuclear stratification, hyperchromasia, and atypical mitoses
• Cellular proliferation creates crowded, cribriform glands
• Normal branching pattern of endocervical glands is preserved
• ~50% of women with AIS have concurrent squamous CIN
• Skip lesions make excision critical (not just ablation)

PRECANCEROUS INTRAEPITHELIAL LESIONS - SUMMARY TABLE

NATURAL HISTORY SUMMARY

    HPV Infection (Transient 9-15 months → 90% clear)
              │
              ▼ (persistent high-risk HPV)
           CIN 1 (LSIL)
         ↗ 60-85% REGRESSION
              │ 10-15% progression (years)
              ▼
           CIN 2 (HSIL)
         ↗ 40% REGRESSION
              │ 20-25% progression (years)
              ▼
           CIN 3 / CIS (HSIL)
         ↗ 30-35% REGRESSION
              │ 5% invasion over years
              ▼
       Invasive Cervical Carcinoma

• HPV → CIN 1: months
• CIN 1 → CIN 3: 2-10 years
• CIN 3 → Invasion: 5-20 years (provides window for prevention)

KEY POINTS TO REMEMBER (Berek & Novak)

1. CIN arises in the TZ at the advancing SCJ - this is where screening and colposcopy focus
2. CIN 1 = HPV effect, not a true precancer; 60-85% regress spontaneously
3. CIN 2/3 = true precancers requiring treatment in most adults ≥25 years
4. LEEP is preferred for CIN 2/3 - gives tissue for histology and rules out invasion
5. Ablation is contraindicated when: colposcopy inadequate, lesion in endocervix, microinvasion suspected, AIS present
6. Pregnancy: No treatment (only observation); treat only if invasive cancer proven
7. Young women (<25): More conservative management; higher spontaneous regression expected
8. Positive margins after cone: 23.6% recurrence with gland involvement vs 11.3% without
9. HPV 16 and 18 account for most CIN 2/3 and invasive cancer
10. Hysterectomy is the last resort - higher complications than conservative treatments

POSTPARTUM CONTRACEPTION

Comprehensive 10-Mark Answer - Berek & Novak's Gynecology

INTRODUCTION

1. Breastfeeding status (lactating vs. non-lactating)
2. Time since delivery (immediate / early / delayed)
3. Desire for future fertility

WHO Medical Eligibility Criteria (MEC) categories are used to guide safety of each method:

• Category 1: No restriction (use freely)
• Category 2: Advantages outweigh risks
• Category 3: Risks outweigh advantages (use with caution)
• Category 4: Unacceptable health risk (do NOT use)

OVERVIEW TABLE: Methods and Timing

FLOWCHART 1: Initial Decision - Postpartum Contraception

        POSTPARTUM WOMAN SEEKING CONTRACEPTION
                        │
                        ▼
              IS SHE BREASTFEEDING?
          ┌─────────────┴──────────────┐
          NO                          YES
          │                            │
          ▼                            ▼
  Non-lactating path           Lactating path
  (see Flowchart 2)            (see Flowchart 3)

FLOWCHART 2: NON-LACTATING WOMAN

NON-LACTATING POSTPARTUM WOMAN
             │
   ┌─────────┼──────────────────────────────┐
   │         │                              │
   ▼         ▼                              ▼
WANTS    WANTS SPACING            WANTS PERMANENT
NOTHING  (Reversible method)       STERILIZATION
NOW           │                        │
   │    ┌─────┴──────┐                 ▼
   │  IMMEDIATE   DELAYED (>4 wks) TUBAL LIGATION
   │  (0-48 hrs)                   (within 24-48h
   │                               postpartum OR
   ▼                               interval after 6 wks)
Counsel   Immediate:
at 6 wks  • Copper IUD (postplacental)
follow-up • LNG-IUD (postplacental)
          • Progestin-only implant
          • DMPA injection
          • Progestin-only pill
          
          After 21 days:
          • COC, patch, ring can be started
          (VTE risk elevated in first 21 days postpartum)

FLOWCHART 3: LACTATING WOMAN

LACTATING (BREASTFEEDING) POSTPARTUM WOMAN
                    │
                    ▼
     Does she meet ALL 3 LAM criteria?
     ┌────────────────────────────────────────────┐
     │ 1. Exclusively breastfeeding (day & night) │
     │ 2. Amenorrhoeic (no menstrual bleed)       │
     │ 3. < 6 months postpartum                   │
     └────────────────────────────────────────────┘
         │
    ┌────┴────┐
   YES        NO
    │          │
    ▼          ▼
  LAM is    Add additional method:
  effective  • Copper IUD (any time)
  (98-99%)   • Progestin-only pill (any time)
             • Progestin-only implant (any time*)
             • DMPA (after 6 weeks)
             • LNG-IUD (caution in first 4 wks)
             • COC ONLY after 6 months postpartum
               (or ≥42 days if not fully breastfeeding)

*Implant: some guidelines say immediate; others advise after 4 wks

INDIVIDUAL METHODS IN DETAIL

1. LACTATIONAL AMENORRHEA METHOD (LAM)

┌──────────────────────────────────────────────────────────┐
│             THE BELLAGIO CONSENSUS (LAM)                 │
│                                                          │
│   ① EXCLUSIVE BREASTFEEDING                              │
│      Day AND night feeds; no supplements                 │
│                                                          │
│   ② AMENORRHEA                                           │
│      No menstrual bleed since delivery                   │
│                                                          │
│   ③ < 6 MONTHS POSTPARTUM                                │
│                                                          │
│   All 3 criteria met = 98-99% efficacy                   │
│   ANY criterion fails → Add backup method                │
└──────────────────────────────────────────────────────────┘

• Mechanism: Frequent suckling suppresses GnRH pulsatility → inhibits LH surge → no ovulation
• When LAM fails: First ovulation typically precedes first menstrual period → woman at risk before she realizes LAM has ceased
• Advise: Add contraception immediately when any criterion is no longer met

2. INTRAUTERINE DEVICES (IUDs)

Types Available:

Postpartum IUD Insertion Timing:

┌─────────────────────────────────────────────────────────────┐
│                   POSTPARTUM IUD TIMING                     │
├─────────────────────┬───────────────────────────────────────┤
│ POSTPLACENTAL       │ Within 10 minutes of placental        │
│ (Immediate)         │ delivery - vaginal or cesarean        │
│                     │ Expulsion rate: 24-27% vaginal        │
│                     │              (lower with C/S)         │
├─────────────────────┼───────────────────────────────────────┤
│ EARLY POSTPARTUM    │ 48 hrs - 4 weeks: NOT recommended     │
│                     │ (uterine involution - higher perf.    │
│                     │  risk, highest expulsion rate)        │
├─────────────────────┼───────────────────────────────────────┤
│ INTERVAL INSERTION  │ After 4-6 weeks postpartum            │
│                     │ Standard insertion technique          │
│                     │ Lower expulsion rate                  │
└─────────────────────┴───────────────────────────────────────┘

• Copper IUD: "Biologic foam" - fibrin, phagocytic cells, proteolytic enzymes + copper ions → interferes with sperm passage, prevents fertilization
• LNG-IUD: Thickens cervical mucus, causes endometrial atrophy, intrauterine inflammatory response

• Pregnancy, puerperal sepsis, active PID/cervicitis
• Undiagnosed genital bleeding
• Gestational trophoblastic disease (elevated β-hCG)
• Uterine anomalies/fibroids distorting cavity
• Copper IUD: copper allergy, Wilson's disease

3. PROGESTIN-ONLY PILL (POP / "Mini-pill")

• Contains only progestin (no estrogen)
• Safe to start from day 1 postpartum in both lactating and non-lactating women
• Does NOT affect milk quality or quantity (Berek & Novak)
• Must be taken at the same time each day (window: 3 hours)
• Mechanism: Primarily thickens cervical mucus; also suppresses ovulation variably

4. DEPOT MEDROXYPROGESTERONE ACETATE (DMPA / Depo-Provera)

NON-LACTATING: Can start IMMEDIATELY postpartum (within 5 days)
LACTATING: Recommended AFTER 6 weeks postpartum

• 150 mg IM every 12 weeks (or 104 mg SC every 12 weeks)
• Efficacy: 99.7%
• Does NOT affect milk quality or quantity (Berek & Novak)
• Advantages: No daily pill, highly effective, may improve endometriosis/menorrhagia
• Disadvantages: Irregular bleeding, delayed return of fertility (up to 18 months), bone density loss with long-term use

5. SUBDERMAL IMPLANT (Etonogestrel / Nexplanon)

• Single rod implanted in inner upper arm
• Most effective contraceptive available: >99.9% (Pearl Index <0.1)
• Duration: 3 years
• Can be inserted immediately postpartum in non-lactating women
• In lactating women: Generally considered safe immediately; progestin implants do not affect breast milk (blood levels comparable to other progestin-only methods)
• Rapid return of fertility after removal
• Irregular bleeding is the most common complaint

6. COMBINED ORAL CONTRACEPTIVES (COC) / PATCH / RING

┌──────────────────────────────────────────────────────────────┐
│            TIMING FOR COMBINED HORMONAL METHODS              │
├──────────────────────────────────────────────────────────────┤
│ NON-LACTATING    │ After 21 days postpartum                  │
│                  │ (VTE risk is elevated in first 21 days)   │
├──────────────────────────────────────────────────────────────┤
│ LACTATING        │ After 6 months postpartum (WHO preferred) │
│                  │ OR ≥ 42 days if not exclusively feeding   │
│                  │ (Estrogen may reduce milk supply)         │
└──────────────────────────────────────────────────────────────┘

1. VTE risk: Postpartum state is already hypercoagulable; estrogen further increases thrombotic risk
2. Milk supply: Estrogen may reduce milk quantity (though evidence is conflicting for modern low-dose pills - Berek & Novak notes combined methods are Category 2 beyond 30 days in breastfeeding women)

7. BARRIER METHODS

• Condoms, diaphragm, cervical cap, spermicides
• Can be started at any time postpartum
• Condoms: Only method that also protects against STIs
• Diaphragm/cap: Fit should be re-assessed after delivery (uterine involution changes anatomy)
• Spermicides: Safe in breastfeeding, but lower efficacy alone (typical use 72%)
• No effect on breastfeeding

8. POSTPARTUM TUBAL STERILIZATION

┌──────────────────────────────────────────────────────────────┐
│                TUBAL STERILIZATION TIMING                    │
├──────────────────────────────────────────────────────────────┤
│ POSTPARTUM      │ Within 24-48 hours of vaginal delivery     │
│ (Minilaparotomy)│ At time of cesarean section (concurrent)   │
│                 │ Uterus still enlarged → fundus near umbilicus│
│                 │ Simple subumbilical incision               │
├──────────────────────────────────────────────────────────────┤
│ INTERVAL        │ At least 6 weeks after delivery            │
│ (Laparoscopy)   │ Standard technique                        │
└──────────────────────────────────────────────────────────────┘

MASTER SUMMARY FLOWCHART: Complete Postpartum Contraception Algorithm

                    POSTPARTUM WOMAN
                          │
          ┌───────────────┴────────────────┐
     BREASTFEEDING?                    NOT BREASTFEEDING
          │                                │
    ┌─────┴──────┐              ┌──────────┼──────────────┐
EXCLUSIVE    PARTIAL/          0-21       21 days -     PERMANENT
(all 3 LAM   NOT BF            days       6 weeks        DECISION?
criteria)                       │           │                │
    │             │             ▼           ▼                ▼
   LAM          Need      Progestin-    ALL methods      Tubal
+              method     only only     available        sterilization/
backup when    now:       (IUD,         (COC/patch/      Vasectomy
criteria        ↓         POP,          ring can
break         Copper      DMPA,         now start)
              IUD or      implant,
              POP or      barriers)
              Implant     
              ──────
              AVOID
              COC until
              6 months
              
KEY RULE: AVOID ESTROGEN (COC/patch/ring) in:
• First 21 days (VTE risk ALL women)
• Lactating women < 6 months (reduces milk)
• Lactating women < 42 days (WHO Cat 4)

EFFICACY COMPARISON TABLE

KEY POINTS TO REMEMBER FOR EXAM (Berek & Novak)

1. LAM is 98-99% effective only when ALL 3 Bellagio criteria are met simultaneously
2. Progestin-only methods (POP, implant, DMPA) do NOT affect breast milk - safe at any postpartum time
3. Copper IUD is the best non-hormonal option; also works as emergency contraception within 5 days
4. Postplacental IUD has higher expulsion (24-27%) but better overall use at 6 months vs. interval insertion
5. COC/estrogen-containing methods: Avoid for 21 days in ALL women (VTE); avoid until 6 months in breastfeeding women (milk supply)
6. DMPA in breastfeeding: Delay until 6 weeks (concerns about neonatal progestin exposure in first days)
7. Immediate postpartum sterilization: Within 24-48 hours via minilaparotomy - uterine fundus near umbilicus makes it simple
8. Salpingectomy is now preferred over tubal ligation - reduces ovarian cancer risk with similar safety
9. HIV-positive women: IUDs are NOT contraindicated - no increase in HIV transmission or disease progression
10. The "gap" in postpartum care: Women scheduled for interval IUD insertion often do not return - immediate postplacental insertion is preferred despite higher expulsion rate

MANAGEMENT OF STAGE I CARCINOMA CERVIX IN PREGNANCY

(G3P2L2 diagnosed at 20 weeks gestation)

10-Mark MS Main Exam Answer - Based on Berek & Novak's Gynecology + Creasy & Resnik's MFM (Williams equivalent)

INTRODUCTION

• Family is complete (2 living children) → fertility preservation is NOT a priority
• The oncologic interest of the mother takes precedence once this is established
• This is an invasive cancer in a previable/borderline viable fetus - the most challenging management window

Incidence: 1.2 in 10,000 pregnancies (Berek & Novak) Diagnosis is often delayed because bleeding is attributed to pregnancy complications

STEP 1 - CONFIRM DIAGNOSIS AND STAGING

SUSPICIOUS PAP / CERVICAL LESION IN PREGNANCY
                    │
                    ▼
          COLPOSCOPY + DIRECTED BIOPSY
         (safe in pregnancy at any gestation)
                    │
              ┌─────┴──────┐
        BIOPSY           COLPOSCOPY
        CONFIRMS          CANNOT RULE
        INVASION          OUT INVASION
              │                │
              ▼                ▼
         CLINICAL          CONIZATION
         STAGING        (NOT before 2nd trimester;
                         abort risk 33% in 1st trimester;
                         perform only if essential)

FIGO 2018 STAGING (applies in pregnancy too):

IMAGING IN PREGNANCY:

• MRI = PREFERRED - safe in pregnancy, best for defining tumor extent and parametrial spread
• Chest X-ray = acceptable (abdominal shielding)
• CT scan - avoid if possible (ionizing radiation); use if MRI unavailable
• PET scan - avoid (safety data in pregnancy lacking)

STEP 2 - THE KEY DECISION FRAMEWORK

"Management of cervical cancer in pregnancy must be individualized. A multidisciplinary team - perinatologist, neonatologist, radiation oncologist, and gynecologic oncologist - should be recruited." (Creasy & Resnik)

Three pivotal questions that determine management:

┌────────────────────────────────────────────────────────────┐
│ QUESTION 1: What is the FIGO STAGE?                        │
│   → IA1 / IA2 / IB1 / IB2 / IB3                          │
├────────────────────────────────────────────────────────────┤
│ QUESTION 2: What is the GESTATIONAL AGE?                   │
│   → <20 wks / 20-28 wks / 28-34 wks / >34 wks            │
├────────────────────────────────────────────────────────────┤
│ QUESTION 3: Does the PATIENT WISH TO CONTINUE PREGNANCY?   │
│   → Yes (delay treatment) / No (immediate treatment)       │
│   → In this case: G3P2L2 - family complete                 │
│      → Counseling should lean toward definitive Rx         │
└────────────────────────────────────────────────────────────┘

MASTER MANAGEMENT FLOWCHART

      G3P2L2, 20 WEEKS, STAGE I CARCINOMA CERVIX
                         │
                         ▼
        ┌────────────────────────────────────┐
        │ MULTIDISCIPLINARY TEAM COUNSELING  │
        │ Explain: prognosis, treatment      │
        │ options, fetal outcomes at 20 wks  │
        │ (fetus currently NOT viable -      │
        │  viability begins ~24 weeks)       │
        └────────────────┬───────────────────┘
                         │
              ┌──────────┴──────────┐
         STAGE IA1/IA2          STAGE IB1/IB2/IB3
              │                       │
     (see Flowchart A)         (see Flowchart B)

FLOWCHART A: STAGE IA1 AND IA2 AT 20 WEEKS

STAGE IA1 (invasion ≤3mm, NO LVSI)
             │
             ▼
  Conization with NEGATIVE MARGINS
  (performed in 2nd trimester, in OT)
             │
    ┌────────┴────────┐
 NEGATIVE          POSITIVE
 MARGINS           MARGINS
    │                   │
    ▼                   ▼
Follow-up          Counsel for
colposcopy         RISK OF RESIDUAL
every trimester    INVASIVE DISEASE
    │               → Repeat cone OR
    ▼               → Definitive therapy
Continue pregnancy
to 32-35 weeks
(fetal lung maturity by amniocentesis)
    │
    ▼
CLASSICAL CESAREAN SECTION
(NOT vaginal delivery - see note*)
    │
    ▼
Postpartum (6 weeks):
EXTRAFASCIAL HYSTERECTOMY
(if no desire for fertility -
 as in this G3P2L2 patient)

──────────────────────────────────────────
STAGE IA1 with LVSI  OR  STAGE IA2
(invasion 3-5 mm)
             │
             ▼
   Does patient want to continue
   pregnancy? (G3P2L2 = family complete
   → may opt to terminate)
             │
    ┌────────┴──────────┐
CONTINUE               TERMINATE / DELIVER
PREGNANCY              IMMEDIATELY
    │                        │
    ▼                        ▼
Follow to fetal          GRAVID RADICAL
maturity (32-35 wks)     HYSTERECTOMY
    │                    + PELVIC LND
    ▼                    (feasible in 1st/2nd
CLASSICAL C/S            trimester)
    │
    ▼
MODIFIED RADICAL
HYSTERECTOMY
+ PELVIC LND
(same sitting after C/S)

FLOWCHART B: STAGE IB AT 20 WEEKS (THE MAIN SCENARIO)

STAGE IB1 / IB2 / IB3 AT 20 WEEKS
              │
              ▼
    ┌──────────────────────────────────────────────┐
    │           PATIENT COUNSELING                 │
    │  • Fetus currently NOT viable (20 wks)       │
    │  • Family complete (G3P2L2)                  │
    │  • Delay of therapy = risk to mother         │
    │  • Immediate therapy = loss of pregnancy     │
    │  • Neoadjuvant chemo option if delay desired │
    └──────────────────┬───────────────────────────┘
                       │
         ┌─────────────┴──────────────────────┐
    OPTION 1                              OPTION 2
    TERMINATE PREGNANCY                   CONTINUE PREGNANCY
    + IMMEDIATE TREATMENT                 (delay definitive Rx)
         │                                     │
         ▼                                     ▼
 STAGE IB1 (small):               NEOADJUVANT CHEMOTHERAPY
 RADICAL HYSTERECTOMY             (cisplatin-based, after 14 wks)
 Type III (Wertheim's)            + Review EVERY 4 WEEKS
 + BILATERAL PELVIC LND           + MRI at 4-6 week intervals
 (preferred if operable)          + Aim for delivery 32-34 weeks
         │                             (when fetal lungs mature)
         ▼                                     │
 STAGE IB2/IB3 (bulky):                       ▼
 CONCURRENT                            CLASSICAL CESAREAN
 CHEMORADIATION                        + RADICAL HYSTERECTOMY
 (Cisplatin + EBRT                       + PELVIC LND
  + Brachytherapy)                     (same sitting or staged)

THE CRITICAL POINTS AT 20 WEEKS (G3P2L2)

┌─────────────────────────────────────────────────────────────────┐
│         RECOMMENDED PATH FOR THIS PATIENT                       │
│                                                                 │
│  Stage IA1 (no LVSI): Can reasonably wait until viability       │
│  ──────────────────────────────────────────────────────────     │
│  Stage IA1 (+ LVSI) / IA2:                                      │
│  → Option to terminate and immediate radical hysterectomy + LND │
│                                                                  │
│  Stage IB1:                                                      │
│  → STRONGLY RECOMMENDED: Terminate pregnancy +                  │
│     WERTHEIM'S RADICAL HYSTERECTOMY + PELVIC LND                │
│  → If patient refuses termination:                               │
│     NEOADJUVANT CHEMO + deliver at 32-34 wks +                  │
│     Classical C/S + Radical Hysterectomy same sitting           │
│                                                                  │
│  Stage IB2/IB3:                                                  │
│  → Terminate pregnancy IMMEDIATELY +                            │
│     CONCURRENT CHEMORADIATION                                   │
│     (Cisplatin 40 mg/m² weekly + EBRT + Brachytherapy)         │
└─────────────────────────────────────────────────────────────────┘

Berek & Novak: "Although timing is controversial, it is probably unwise to delay therapy for longer than 4 weeks."

Creasy & Resnik: "Intentional delays in treatment have been reported from 6 to 32 weeks for women with Stage I-II disease without significant compromise in outcome - but careful counseling and documentation are imperative."

MODE OF DELIVERY

┌──────────────────────────────────────────────────────────┐
│         VAGINAL DELIVERY - CONTRAINDICATED               │
│                                                          │
│  Berek & Novak (multivariate analysis of 56 women):      │
│  "Vaginal delivery was the MOST SIGNIFICANT              │
│   PREDICTOR OF RECURRENCE in women with cervical         │
│   cancer diagnosed during pregnancy."                    │
│                                                          │
│  Most recurrences after vaginal delivery = DISTANT SITES │
│  (including episiotomy site metastasis - rare but real)  │
└──────────────────────────────────────────────────────────┘

CESAREAN SECTION: CLASSICAL (VERTICAL UTERINE) INCISION
• Avoids cervical trauma
• Avoids tumor dissemination
• Allows immediate access for radical hysterectomy
• Classical = vertical fundal incision (NOT lower segment)
  → lower segment is in close proximity to the tumor

SURGICAL PROCEDURE: WERTHEIM'S RADICAL HYSTERECTOMY

CLASSICAL CESAREAN SECTION (vertical incision)
              │
              ▼ (immediate, same anesthesia)
WERTHEIM'S RADICAL HYSTERECTOMY (TYPE III)
              │
    ┌─────────┼──────────────────────────────┐
    │         │                              │
    ▼         ▼                              ▼
UTERUS    BILATERAL              UPPER 1/3 VAGINA
CERVIX    PARAMETRIA             (2-3 cm cuff)
+         (medial, middle
TUBES     parametrium
+         resected to
OVARIES   lateral pelvic
(may be   wall)
conserved
in young
patients)
              │
              ▼
  BILATERAL PELVIC LYMPHADENECTOMY
  (external iliac, internal iliac,
   obturator nodes)
              │
              ▼
  Specimen sent for frozen section
  → If nodes POSITIVE: Add adjuvant
    CHEMORADIATION postoperatively
  → If margins POSITIVE: Add
    adjuvant CHEMORADIATION

NEOADJUVANT CHEMOTHERAPY (If Patient Opts to Continue Pregnancy)

Berek & Novak: "Neoadjuvant chemotherapy has been administered to women during pregnancy with cervical cancer after 13 weeks gestation, without clear short-term harm to the fetus."

Creasy & Resnik: "Neoadjuvant chemotherapy can be used for women electing to continue pregnancy who may be deemed high risk for adverse outcomes with delay in therapy."

NEOADJUVANT CHEMOTHERAPY PROTOCOL:
─────────────────────────────────────────────────────
Drug: CISPLATIN (± Paclitaxel or Vinblastine)
Timing: ONLY after 14 weeks (organogenesis complete)
Route: Intravenous
Monitoring: Fetal ultrasound + growth surveillance
            Maternal CBC, renal function each cycle
Goal: Tumor stabilization/downsizing until fetal maturity
─────────────────────────────────────────────────────

FETAL DELIVERY TARGET:
• 32 weeks: 75% neonatal survival (modern NICU care)
• 34 weeks: ~90% neonatal survival
• Fetal lung maturity: Confirmed by AMNIOCENTESIS
  before delivery

POSTPARTUM MANAGEMENT SUMMARY

PROGNOSIS (Berek & Novak)

PROGNOSIS IN CERVICAL CANCER IN PREGNANCY:
────────────────────────────────────────────
• Stage is the MOST IMPORTANT prognostic factor
• OS is SLIGHTLY BETTER than non-pregnant patients
  (because higher proportion have Stage I disease)
• ADVANCED DISEASE: Pregnancy IMPAIRS prognosis
• POSTPARTUM DIAGNOSIS: Associated with more
  advanced stage + DECREASED SURVIVAL
  (diagnosis often delayed)
────────────────────────────────────────────
5-Year Survival by Stage (approximate):
  IA1: >95%
  IA2: 85-95%
  IB1: 80-90%
  IB2: 75-85%
  IB3: 70-80%

SUMMARY TABLE: STAGE I CERVIX IN PREGNANCY AT 20 WEEKS (G3P2L2)

KEY EXAM POINTS - DO NOT MISS

1. Vaginal delivery is CONTRAINDICATED in any stage cervical cancer - it is the single most significant predictor of recurrence (Berek & Novak)
2. Classical (vertical) cesarean incision is used - NOT lower segment (tumor proximity)
3. At 20 weeks the fetus is NOT viable - this strongly influences toward immediate definitive treatment
4. G3P2L2 = family complete - fertility preservation (trachelectomy) is NOT indicated
5. Radical trachelectomy in pregnancy is NOT recommended - up to 20% pregnancy loss (Creasy & Resnik)
6. Delay of therapy >4 weeks is unwise (Berek & Novak) - however up to 16-32 weeks delay has been reported in select Stage I-II cases with similar outcomes
7. MRI is the imaging of choice in pregnancy for staging
8. Neoadjuvant chemotherapy only after 14 weeks (organogenesis complete) - cisplatin-based
9. If surgery done, frozen section of nodes - positive nodes → add adjuvant chemoradiation
10. Multidisciplinary team is mandatory: Gynecologic oncologist + Perinatologist + Neonatologist + Radiation oncologist

1. Berek & Novak's Gynecology - available ✓
2. Creasy & Resnik's Maternal-Fetal Medicine - available ✓

1. Berek & Novak only (strictly attributed)
2. Berek & Novak + Creasy & Resnik (same content, clearly labeled)